INFUGEM - (1200MG/120ML, 1300MG/130ML, 1400MG/140ML, 1500MG/150ML, 1600MG/160ML, 1700MG/170ML, 1800MG/180ML, 1900MG/190ML, 2000MG/200ML, 2200MG/220ML - Solution)

Generic Name	GEMCITABINE HYDROCHLORIDE	**Innovator**	Sun Pharma
Dosage	1200MG/120ML, 1300MG/130ML, 1400MG/140ML, 1500MG/150ML, 1600MG/160ML, 1700MG/170ML, 1800MG/180ML, 1900MG/190ML, 2000MG/200ML, 2200MG/220ML - Solution	**Branded US Sales**	Less Than $1000 mn
Probable FTF	None	**Known Para IV Filers**	None
Other ANDA developers	None	**Tentative Approvals**	None
Final Approvals	None	**Generic Launches**	None
Indication	INFUGEM is a nucleoside metabolic inhibitor indicated: ? in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. ? in combination with paclitaxel, for first-line treatment of metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. ? in combination with cisplatin, for the treatment of non-small cell lung cancer. (1.3) ? as a single agent for the treatment of pancreatic cancer.		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.